Current concepts and controversies in the pathogenesis of Parkinson’s disease dementia and Dementia with Lewy Bodies
暂无分享,去创建一个
J. Schott | A. Schrag | R. Weil | J. Bras | T. Lashley
[1] S. Galetta,et al. Editors' note: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium , 2018, Neurology.
[2] L. Volpicelli-Daley. Effects of α-synuclein on axonal transport , 2017, Neurobiology of Disease.
[3] Alan J. Thomas,et al. Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.
[4] T. Montine,et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis , 2017, The Lancet Neurology.
[5] J. Schott,et al. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study , 2017, The Lancet Neurology.
[6] Jean-François Dartigues,et al. Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing , 2017, Genome Biology.
[7] D. James Surmeier,et al. Selective neuronal vulnerability in Parkinson disease , 2017, Nature Reviews Neuroscience.
[8] H. Berendse,et al. Distribution and Load of Amyloid-&bgr; Pathology in Parkinson Disease and Dementia with Lewy Bodies , 2016, Journal of neuropathology and experimental neurology.
[9] G. Deuschl,et al. Abolishing the 1‐year rule: How much evidence will be enough? , 2016, Movement disorders : official journal of the Movement Disorder Society.
[10] J. Hardy,et al. The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.
[11] Michelle K. Lupton,et al. Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases , 2016, Neurobiology of Aging.
[12] S. Murayama,et al. Lewy body pathology involves the olfactory cells in Parkinson's disease and related disorders , 2016, Movement disorders : official journal of the Movement Disorder Society.
[13] M. Vidailhet,et al. Sleep aspects on video‐polysomnography in LRRK2 mutation carriers , 2015, Movement disorders : official journal of the Movement Disorder Society.
[14] H. Reichmann,et al. Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors , 2015, Nature Reviews Neurology.
[15] Toshiki Uchihara,et al. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies , 2015, Acta Neuropathologica.
[16] A. Desautels,et al. GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder , 2015, Annals of clinical and translational neurology.
[17] W. Schulz-Schaeffer. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson’s Disease? , 2015, Biomolecules.
[18] Mark P. MacEachern,et al. Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review , 2015, Movement disorders : official journal of the Movement Disorder Society.
[19] Richard Wade-Martins,et al. Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. , 2015, Trends in biochemical sciences.
[20] K. Gamble,et al. Formation of α-synuclein Lewy neurite–like aggregates in axons impedes the transport of distinct endosomes , 2014, Molecular biology of the cell.
[21] S. Love,et al. Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson’s disease , 2014, Alzheimer's Research & Therapy.
[22] T. Hortobágyi,et al. Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias , 2014, Brain pathology.
[23] K. Kosaka. Lewy body disease and dementia with Lewy bodies , 2014, Proceedings of the Japan Academy. Series B, Physical and biological sciences.
[24] Jia-Yi Li,et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats , 2014, Acta Neuropathologica.
[25] H. Groenewegen,et al. Stage‐dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.
[26] S. Gomperts. Imaging the Role of Amyloid in PD Dementia and Dementia with Lewy Bodies , 2014, Current Neurology and Neuroscience Reports.
[27] W. M. van der Flier,et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies , 2014, Human molecular genetics.
[28] Hao Wu,et al. Complete morphologies of basal forebrain cholinergic neurons in the mouse , 2014, eLife.
[29] C. Adler,et al. The neurobiological basis of cognitive impairment in Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.
[30] C. Meshul,et al. Presynaptic Alpha-Synuclein Aggregation in a Mouse Model of Parkinson's Disease , 2014, The Journal of Neuroscience.
[31] G. Legname,et al. In vitro aggregation assays for the characterization of α-synuclein prion-like properties , 2014, Prion.
[32] M. Jahanshahi,et al. The nucleus basalis of Meynert: A new target for deep brain stimulation in dementia? , 2013, Neuroscience & Biobehavioral Reviews.
[33] Nick C Fox,et al. Molecular nexopathies: a new paradigm of neurodegenerative disease , 2013, Trends in Neurosciences.
[34] Bin Zhang,et al. Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons , 2013, Cell.
[35] D. Surmeier,et al. Neuronal vulnerability, pathogenesis, and Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.
[36] M. Nalls,et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. , 2013, JAMA neurology.
[37] Mohamad Saad,et al. Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. , 2013, Human molecular genetics.
[38] Masato Hasegawa,et al. Prion-like spreading of pathological α-synuclein in brain , 2013, Brain : a journal of neurology.
[39] Daniela Boassa,et al. Mapping the Subcellular Distribution of α-Synuclein in Neurons using Genetically Encoded Probes for Correlated Light and Electron Microscopy: Implications for Parkinson's Disease Pathogenesis , 2013, The Journal of Neuroscience.
[40] H. Shill,et al. Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains , 2013, Experimental Neurology.
[41] L. White,et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease , 2012, Neurology.
[42] K. Jellinger. Neurobiology of cognitive impairment in Parkinson’s disease , 2012, Expert review of neurotherapeutics.
[43] J. Trojanowski,et al. Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.
[44] K. Berman,et al. The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. , 2012, Brain : a journal of neurology.
[45] J. Kordower,et al. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. , 2012, Brain : a journal of neurology.
[46] Sachie K. Ogawa,et al. Whole-Brain Mapping of Direct Inputs to Midbrain Dopamine Neurons , 2012, Neuron.
[47] J. Trojanowski,et al. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice , 2012, The Journal of experimental medicine.
[48] K. Jellinger. Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts , 2012, Movement disorders : official journal of the Movement Disorder Society.
[49] T. Uchihara,et al. Pale Neurites, Premature α‐Synuclein Aggregates with Centripetal Extension from Axon Collaterals , 2012, Brain pathology.
[50] E. Waxman,et al. E46K Human α-Synuclein Transgenic Mice Develop Lewy-like and Tau Pathology Associated with Age-dependent, Detrimental Motor Impairment* , 2011, The Journal of Biological Chemistry.
[51] D. Dickson,et al. Neuropathology underlying clinical variability in patients with synucleinopathies , 2011, Acta Neuropathologica.
[52] Constantinos Kallis,et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? , 2011, Brain : a journal of neurology.
[53] C. Lowry,et al. Functional topography of midbrain and pontine serotonergic systems: implications for synaptic regulation of serotonergic circuits , 2011, Psychopharmacology.
[54] K. Blennow,et al. The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia , 2011, International journal of geriatric psychiatry.
[55] T. Iwatsubo,et al. Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. , 2010, The Journal of biological chemistry.
[56] B. Ghetti,et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. , 2010, Brain : a journal of neurology.
[57] W. Schulz-Schaeffer. The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia , 2010, Acta Neuropathologica.
[58] R. Burke,et al. Clinical progression in Parkinson disease and the neurobiology of axons , 2010, Annals of neurology.
[59] A. Kakita,et al. Proteinase K-resistant α-synuclein is deposited in presynapses in human Lewy body disease and A53T α-synuclein transgenic mice , 2010, Acta Neuropathologica.
[60] D. Dickson,et al. Neuropathology of non-motor features of Parkinson disease. , 2009, Parkinsonism & related disorders.
[61] J. Trojanowski,et al. Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells , 2009, Proceedings of the National Academy of Sciences.
[62] J. Callaway,et al. Endogenous calcium buffering capacity of substantia nigral dopamine neurons. , 2009, Journal of neurophysiology.
[63] T. Duka,et al. α‐Synuclein contributes to GSK‐3β‐catalyzed Tau phosphorylation in Parkinson's disease models , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[64] Dag Aarsland,et al. Parkinson Disease With Dementia: Comparing Patients With and Without Alzheimer Pathology , 2009, Alzheimer disease and associated disorders.
[65] K. Jellinger. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. , 2009, Biochimica et biophysica acta.
[66] R. Burke,et al. Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease , 2009, Nature Neuroscience.
[67] H. Shill,et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction , 2009, Acta Neuropathologica.
[68] Ole Isacson,et al. Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy , 2009, The Journal of Neuroscience.
[69] F. Fujiyama,et al. Single Nigrostriatal Dopaminergic Neurons Form Widely Spread and Highly Dense Axonal Arborizations in the Neostriatum , 2009, The Journal of Neuroscience.
[70] R. Hauser,et al. Transplanted dopaminergic neurons develop PD pathologic changes: A second case report , 2008, Movement disorders : official journal of the Movement Disorder Society.
[71] P. Calabresi,et al. Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies , 2008, Biological Psychiatry.
[72] H. Budka,et al. Nigral burden of α‐synuclein correlates with striatal dopamine deficit , 2008, Movement disorders : official journal of the Movement Disorder Society.
[73] C. Rowe,et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[74] E. Tolosa,et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.
[75] G. Halliday,et al. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years , 2008, Movement disorders : official journal of the Movement Disorder Society.
[76] Alain Dagher,et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years , 2008, Nature Medicine.
[77] Elisabet Englund,et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.
[78] T. Iwatsubo,et al. Relationship of phosphorylated α-synuclein and tau accumulation to Aβ deposition in the cerebral cortex of dementia with Lewy bodies , 2008, Experimental Neurology.
[79] Michael L. Kramer,et al. Selective detection, quantification, and subcellular location of alpha-synuclein aggregates with a protein aggregate filtration assay. , 2008, BioTechniques.
[80] Satoshi Orimo,et al. Axonal α-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease , 2008 .
[81] K. Jellinger,et al. Predictors of Survival in Dementia with Lewy Bodies and Parkinson Dementia , 2007, Neurodegenerative Diseases.
[82] E. Tolosa,et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[83] D. Westaway,et al. Enhanced accumulation of phosphorylated α‐synuclein in double transgenic mice expressing mutant β‐amyloid precursor protein and presenilin‐1 , 2007 .
[84] Michael L. Kramer,et al. Presynaptic α-Synuclein Aggregates, Not Lewy Bodies, Cause Neurodegeneration in Dementia with Lewy Bodies , 2007, The Journal of Neuroscience.
[85] E. Perry,et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum , 2006, Neurology.
[86] J. Morris,et al. Clinical phenotype of Parkinson disease dementia , 2006, Neurology.
[87] H. Braak,et al. Cognitive decline correlates with neuropathological stage in Parkinson's disease , 2006, Journal of the Neurological Sciences.
[88] R. Barbour,et al. Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.
[89] T. Duka,et al. The neurotoxin, MPP+, induces hyperphosphorylation ofTau, in the presence of α-Synuclein, in SH-SY5Y neuroblastoma cells , 2006, Neurotoxicity Research.
[90] G. Schellenberg,et al. Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. , 2006, Archives of neurology.
[91] J. E. Bell,et al. Evidence of a breakdown of corticostriatal connections in Parkinson’s disease , 2005, Neuroscience.
[92] E B Larson,et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both , 2005, Neurology.
[93] Satoshi Orimo,et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease , 2005, Acta Neuropathologica.
[94] T. Montine,et al. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease , 2005, Neurology.
[95] D. Perl,et al. Lewy-body formation is an aggresome-related process: a hypothesis , 2004, The Lancet Neurology.
[96] H. Braak,et al. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.
[97] K. Blennow,et al. CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.
[98] D. Selkoe. Alzheimer's Disease Is a Synaptic Failure , 2002, Science.
[99] Udo Rüb,et al. Where Does Parkinson Disease Pathology Begin in the Brain? , 2002, Journal of neuropathology and experimental neurology.
[100] B. Holdorff. Friedrich Heinrich Lewy (1885–1950) and His Work , 2002, Journal of the history of the neurosciences.
[101] E. Masliah,et al. α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.
[102] Makoto Hashimoto,et al. β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[103] T. Bayer,et al. Lewy body variant of Alzheimer's disease: α‐synuclein in dystrophic neurites of Aβ plaques , 2000 .
[104] D. Dickson,et al. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease , 2000, Acta Neuropathologica.
[105] J. Gilbert,et al. Lewy body and Alzheimer pathology in a family with the amyloid-β precursor protein APP717 gene mutation , 2000, Acta Neuropathologica.
[106] J Q Trojanowski,et al. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[107] J. Growdon,et al. Clinical and quantitative pathologic correlates of dementia with Lewy bodies , 1999, Neurology.
[108] P. Højrup,et al. α-Synuclein Binds to Tau and Stimulates the Protein Kinase A-catalyzed Tau Phosphorylation of Serine Residues 262 and 356* , 1999, The Journal of Biological Chemistry.
[109] O. Hornykiewicz. Biochemical aspects of Parkinson's disease , 1998, Neurology.
[110] R. Levy,et al. The Lewy-Body Variant of Alzheimer's Disease , 1993, British Journal of Psychiatry.
[111] D. Dickson,et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease , 1991, Neurology.
[112] K. Kosaka,et al. Diffuse lewy body disease in Japan , 1990, Journal of Neurology.
[113] L. Thal,et al. The Lewy body variant of Alzheimer's disease , 1990, Neurology.
[114] Y. Agid,et al. Striatal dopamine deficiency in parkinson's disease: Role of aging , 1989, Annals of neurology.
[115] S. Kish,et al. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.
[116] E. Perry,et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. , 1985, Journal of neurology, neurosurgery, and psychiatry.
[117] T. Tomita,et al. Dense core vesicles around the Lewy body in incidental Parkinson's disease: an electron microscopic study , 1977, Acta Neuropathologica.
[118] L. Forno,et al. Ultrastructure of Lewy bodies in the stellate ganglion , 1976, Acta Neuropathologica.
[119] K. Jellinger,et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.
[120] C. Heald. Paralysis Agitans , 1932, Proceedings of the Royal Society of Medicine.
[121] W. M. van der Flier,et al. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. , 2016, Journal of Alzheimer's disease : JAD.
[122] E. Valente,et al. Phenotypic spectrum of alpha-synuclein mutations: New insights from patients and cellular models. , 2016, Parkinsonism & related disorders.
[123] D. Dickson,et al. Autosomal dominant Parkinson's disease caused by SNCA duplications. , 2016, Parkinsonism & related disorders.
[124] A. Kakita,et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. , 2008, Brain : a journal of neurology.
[125] D. Westaway,et al. Enhanced accumulation of phosphorylated alpha-synuclein in double transgenic mice expressing mutant beta-amyloid precursor protein and presenilin-1. , 2007, Journal of neuroscience research.
[126] D. Dickson,et al. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology. , 2007, Parkinsonism & related disorders.
[127] Michael L. Kramer,et al. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[128] A. Parent,et al. Relationship between axonal collateralization and neuronal degeneration in basal ganglia. , 2006, Journal of neural transmission. Supplementum.
[129] E. Masliah,et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. , 2002, Nature cell biology.
[130] L. Mucke,et al. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[131] T. Bayer,et al. Lewy body variant of Alzheimer's disease: alpha-synuclein in dystrophic neurites of A beta plaques. , 2000, Neuroreport.
[132] M G Spillantini,et al. Alpha-synuclein in Lewy bodies. , 1997, Nature.
[133] F. Lewy. Paralysis agitans. I. Pathologische Anatomie , 1912 .